Will Focus on High-Growth Segments of Advanced Therapeutics Manufacturing and Consolidate Operations

Legal Proceedings to Wind Down Underutilized Sites Do Not Include Resilience or Its Go-Forward Manufacturing Operations Anchored by Cincinnati Facility

Existing Institutional Investors Provided $250 Million in Bridge Financing to Support Transformation

National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and financing in a letter to its customers.

The full letter follows:

Dear Resilience Customers,

Since our founding in 2020, Resilience has focused on improving the pharmaceutical supply chain and providing manufacturers of complex, advanced medicines the ability to produce drugs at scale and on shore. During this time, we have been consistently evolving to capture the market opportunities that match our resources and capabilities with our customers’ priorities.

Most recently, we have determined that the best use of our expertise, resources, and talent is to focus on high-growth segments to advance cell-based medicines, primarily biologics, and aseptic drug product operations. It has also become clear that our capacity expansion has outpaced industry demand. As a result, we have been consolidating our operations to pursue a tailored business strategy with a streamlined footprint.

To advance our transformation while continuing to serve our customers with excellence, it was determined that sites not being fully utilized needed to be wound down in a prompt and efficient manner through legal proceedings commenced by a leaseholder affiliate.

Importantly, Resilience and our go-forward manufacturing operations, anchored by our Cincinnati facility, are fully operational and not included in those proceedings.

Of note, our transformation has the support of our shareholders, with a consortium of existing institutional investors having provided $250 million in bridge financing to support the consolidation of our manufacturing footprint. We are also pursuing additional debt financing to fuel our longer-term growth plans.

Resilience is on track to become a leaner, stronger enterprise, with the right focus and the right footprint to serve you even better in the future. Thank you for your continued partnership during our transformation journey.

Sincerely,

William S. Marth, RPh., MBA

President & Chief Executive Officer

About Resilience

Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably. The company is building a streamlined, high-performance network designed to meet the evolving needs of clinical and commercial-stage innovators. For more information, visit https://resilience.com/ and follow us on social media: Resilience on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250609219371/en/